Jim Birchenough

In a report published Wednesday, BMO Capital Markets analyst Jim Birchenough reiterated an Outperform rating on Intercept Pharmaceuticals (NASDAQ: ICPT), and raised the price target from $44.00 to $62.00. In the report, BMO Capital Markets noted, “ICPT reported 2Q13 operating results today and...

In a report published Wednesday, BMO Capital Markets analyst Jim Birchenough reiterated an Outperform rating on Ambit Biosciences (NASDAQ: AMBI), and raised the price target from $10.00 to $23.00. In the report, BMO Capital Markets noted, “Ambit Biosciences (AMBI) reported 2Q13 operating...

In a report published Wednesday, BMO Capital Markets analyst Jim Birchenough downgraded the rating on Tesaro (NASDAQ: TSRO) from Outperform to Market Perform, but reiterated the $36.00 price target. In the report, BMO Capital Markets noted, “We are lowering our rating on TSRO to Market Perform...

Analysts Jim Birchenough, and Ryan Martins at Barclays Capital (ADR) (NYSE: BCS) have maintained a 1-Overweight rating for Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) on the back of a better-than-expected deal with AstraZeneca plc (ADR) (NYSE: AZN). According to analysts, the deal is one of the...

Following presentation of Phase I data for pan Bcr-Abl inhibitor -534 in advanced hematological cancers at ASH, Barclays has reiterated its Overweight rating for ARIAD Pharmaceuticals (NASDAQ: ARIA). Data presented in heavily pretreated CML pts including pts with the T315I mutation were impressive...

Jim Birchenough of Barclays Capital maintains his "overweight" rating for Genzyme General (NASDAQ: GENZ). The target price for GENZ is set to $63. GENZ indicated that it has received the complete FDA response for Lumizyme and it will file its response within the fortnight. GENZ remains on track to...